airPharma and Bespak sign inhalation deal

Published: 1-Apr-2005


Speciality respiratory pharmaceutical company airPharma has signed an agreement with Bespak to develop and manufacture a new inhalation device for the company's dry powder formulation of Zofac (Pumactant). Bespak will create an improved device based upon technology licensed by airPharma from UK-based Britannia Pharmaceuticals.

airPharma will utilise Bespak's expertise in concept creation, prototyping, design, development, and scientific and manufacturing services to develop refined inhalation delivery devices for phase II clinical studies of Zofac later this year.

Zofac is a protein-free synthetic surfactant made from naturally occurring phospholipids. When inhaled, the powder is believed to create a barrier that may protect the lungs from inhaled allergens, dust and other environmental particulates.

You may also like